![Douglas Williams](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Douglas Williams
Vorstandsvorsitzender bei
CODIAK BIOSCIENCES
Vermögen: 10 929 $ am 30.06.2026
Profil
Douglas E.
Williams is President & Chief Executive Officer at Codiak BioSciences, Inc. since 2015.
He is Chief Executive Officer at TriArm Therapeutics (Taiwan) Ltd. and Triarm Therapeutics Ltd. starting in 2024.
He serves as Chairman at Xenikos BV, Climb Bio, Inc. (since 2024), and CAMP4 Therapeutics Corp.
(starting 2025).
He is Director at eGenesis, Inc., Cygnal Therapeutics, Inc., Cytoimmune Therapeutics, Inc. (since 2021), Panacea Acquisition Corp.
II (since 2021), and Stablix, Inc. (since 2023).
Former roles include Chief Executive Officer & Director at ZymoGenetics, Inc. (2009–2010), Director, Chief Technology Officer & Executive VP at Immunex Corp.
(1988–2002), Director at Array BioPharma, Inc. (2004–2011), Director, Chief Scientific Officer, EVP-R&D at Seagen, Inc. (2002–2005), Director at Anadys Pharmaceuticals, Inc. (2004–2009), Independent Director at Ironwood Pharmaceuticals, Inc. (2014–2019), Director at Aerovance, Inc., Independent Director at Cascadian Therapeutics LLC (2011–2013), Independent Director at Ovid Therapeutics, Inc. (2016–2021), Independent Non-Executive Director at AC Immune SA (2018–2025), Director at Regulus Therapeutics, Inc. (2012–2017), Senior Vice President at Amgen, Inc. (2002–2003), Executive Vice President-Research & Development at Biogen, Inc. (2011–2015), Head-Health & Strategic Development at Genesis Research & Development Corp.
Ltd. (2002–2003), Executive Vice President at Biogen Idec New Ventures, Inc., Secretary & Trustee at Fred Hutchinson Cancer Research Center, and Executive VP, President-Research & Development at Sana Biotechnology, Inc. (2023–2024).
Education includes a doctorate from State University of New York at Buffalo, and undergraduate degrees from the University of Massachusetts Lowell and The Indiana University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.06.2026 | 2’501 ( 0.01% ) | 10 929 $ | 30.06.2026 | |
CLIMB BIO, INC. -.--% | 05.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Douglas Williams
| Unternehmen | Position | Beginn |
|---|---|---|
| CODIAK BIOSCIENCES | Vorstandsvorsitzender | 01.08.2015 |
| PANACEA ACQUISITION CORP. II | Direktor/Vorstandsmitglied | 06.04.2021 |
| HUMORIGIN BIOTECHNOLOGY CORP | Vorstandsvorsitzender | 09.09.2024 |
| CLIMB BIO, INC. | Vorsitzender | 11.11.2024 |
| CAMP4 THERAPEUTICS CORPORATION | Vorsitzender | 10.09.2025 |
eGenesis, Inc.
 eGenesis, Inc. Medical/Nursing ServicesHealth Services Operates as a biotechnology company that provides organs and cells transplantation services | Direktor/Vorstandsmitglied | - |
Triarm Therapeutics Ltd.
 Triarm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures cell based therapeutics products | Vorstandsvorsitzender | 09.09.2024 |
Stablix, Inc.
 Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a preclinical stage biotechnology company, which pioneering small molecule medicines for targeted protein stabilization | Direktor/Vorstandsmitglied | 18.01.2023 |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cancer immunotherapy products | Direktor/Vorstandsmitglied | 15.06.2021 |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░ | - |
Ehemalige bekannte Positionen von Douglas Williams
| Unternehmen | Position | Ende |
|---|---|---|
| ░░ ░░░░░░ ░░ | ░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Douglas Williams
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
75
Beziehungen ersten Grades
31
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 31 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Manufactures, markets, and researches therapeutic products | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops & commercializes biopharmaceutical drugs | Health Technology |
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes cancer medicines | Health Technology |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel small molecule medicines | Health Technology |
Ironwood Pharmaceuticals, Inc.
 Ironwood Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets gastrointestinal products | Health Technology |
Aerovance, Inc.
 Aerovance, Inc. Medical DistributorsDistribution Services Develops drugs for respiratory and inflammatory diseases | Distribution Services |
AC Immune SA
 AC Immune SA Pharmaceuticals: MajorHealth Technology Manufactures precision medicines for neurodegenerative diseases | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Develops therapeutic products for the treatment of cancer | Health Technology |
Ovid Therapeutics, Inc.
 Ovid Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides medicines to children and adults with neurological disorders | Health Technology |
Genesis Research & Development Corp. Ltd.
 Genesis Research & Development Corp. Ltd. Financial ConglomeratesFinance Operates as a development stage company | Finance |
State University of New York at Buffalo
 State University of New York at Buffalo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
Fred Hutchinson Cancer Research Center
 Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Provides research and testing services | Commercial Services |
Regulus Therapeutics, Inc.
 Regulus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in discovering and developing of drugs | Health Technology |
University of Massachusetts Lowell
 University of Massachusetts Lowell Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Develops medicines based on the action of antibodies | Health Technology |
The Indiana University School of Medicine
 The Indiana University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TriArm Therapeutics (Taiwan) Ltd.
 TriArm Therapeutics (Taiwan) Ltd. BiotechnologyHealth Technology Engages in the research and development of biotech new drugs | Health Technology |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
eGenesis, Inc.
eGenesis, Inc. Medical/Nursing ServicesHealth Services Operates as a biotechnology company that provides organs and cells transplantation services | Health Services |
Camp4 Therapeutics Corp.
 Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
Cygnal Therapeutics, Inc.
 Cygnal Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops drugs for treatments of cancer, immune-inflammatory disorders, fibrotic and degenerative diseases | Health Technology |
Sana Biotechnology, Inc.
 Sana Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnological company which creates and delivers engineered cells as medicine for patients | Health Technology |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
Triarm Therapeutics Ltd.
Triarm Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures cell based therapeutics products | Health Technology |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cancer immunotherapy products | Health Technology |
Panacea Acquisition Corp. II
 Panacea Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
Stablix, Inc.
Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a preclinical stage biotechnology company, which pioneering small molecule medicines for targeted protein stabilization | Commercial Services |
